Risk factors and molecular characterization of carbapenem resistant Escherichia coli recovered from a tertiary hospital in Fujian, China from 2021 to 2023.

Siyan Lian, Chang Liu, Meili Cai, Yingping Cao, Xiaohong Xu
Author Information
  1. Siyan Lian: Department of Laboratory Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China.
  2. Chang Liu: Department of Clinical Laboratory, Jianou Hospital, Fujian, People's Republic of China.
  3. Meili Cai: Department of Laboratory Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China.
  4. Yingping Cao: Department of Laboratory Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China. caoyingping@aliyun.com.
  5. Xiaohong Xu: Department of Laboratory Medicine, Fujian Medical University Union Hospital, Fuzhou, Fujian, People's Republic of China. vancy1988@163.com.

Abstract

BACKGROUND: There is a serious public health concern regarding the emergence of carbapenem-resistant Escherichia coli (CREC). The purpose of this study is to identify the molecular characterization and risk factors of CREC in Fujian province, China.
METHODS: A total of 48 CREC isolates were collected from various clinical samples. The strains were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS). Susceptibility to antibiotics was determined by the standard broth microdilution method. Polymerase chain reaction (PCR) was used to screen common drug resistance genes. Multilocus sequence typing (MLST) was used to type isolates. RT-qPCR was used to detect gene expression of acrA, acrB, and tolC. Conjugation assays were used to analyze the transferability of plasmids carrying mcr-1 or bla. Risk factors for CREC infection were identified by logistic regression analysis.
RESULTS: 48 CREC strains were collected, with 81.25% producing carbapenemase (CP-CREC), and 18.75% were not producing carbapenemase (no-CP-CREC). They belonged to 21 sequence type (STs) and five unknown STs. Perianal swabs were the main sample type, with 25 patients found to have hematological malignancies. All isolates of CP-CREC were found to contain bla (bla (n = 32), bla (n = 5), bla (n = 1), and bla (n = 1)), among which one isolate co-existence bla and bla. Two bla-positive strains, specifically bla and bla, were found to co-habor mcr-1 with ST617. Conjugation assays confirmed that bla, bla, and most bla(68.75%, 22/32) could be transferred between E. coli strains. Four of the 9 non-CP-CREC isolates had deletions in ompC and ompF with bla production, while the other five showed high expression of acrA, acrB, and tolC. Antibiotics usage, antifungal treatment, detection of other pathogens (prior to CREC infection), and respiratory disease were identified as independent risk factors for CREC infection. The area under the receiver operating characteristic curve for the scoring system was 0.937. Youden's index, with sensitivity and specificity of 0.96 and 0.78, was maximal when 2 points were scored.
CONCLUSIONS: In CP-CREC, carbapenem resistance is caused primarily by multiple types of bla, while non-CP-CREC is caused by loss of porin protein or high expression of efflux pumps coupled with carrying bla. CREC isolates were highly diverse in terms of ST, with a total of 21 STs identified. Here, we first describe a clinical strain of CREC from China both mcr-1 and bla with ST617. An easy-to-use scoring system was developed to diagnose CREC infections.

Keywords

References

  1. Antimicrob Resist Infect Control. 2019 Dec 30;8:208 [PMID: 31893042]
  2. BMC Microbiol. 2019 Sep 5;19(1):210 [PMID: 31488061]
  3. Front Microbiol. 2020 Feb 11;11:121 [PMID: 32117144]
  4. J Hosp Infect. 2014 Aug;87(4):234-40 [PMID: 25027563]
  5. J Glob Antimicrob Resist. 2024 Jun;37:28-36 [PMID: 38412919]
  6. Front Microbiol. 2017 Jun 13;8:1061 [PMID: 28659886]
  7. Ann Clin Microbiol Antimicrob. 2023 Jan 10;22(1):3 [PMID: 36627626]
  8. Antibiotics (Basel). 2024 Feb 13;13(2): [PMID: 38391571]
  9. Commun Biol. 2024 Jan 6;7(1):51 [PMID: 38184739]
  10. Lancet Infect Dis. 2017 Feb;17(2):153-163 [PMID: 27866944]
  11. PLoS One. 2018 Sep 6;13(9):e0203323 [PMID: 30188911]
  12. Emerg Microbes Infect. 2020 Dec;9(1):237-245 [PMID: 31996107]
  13. Infect Drug Resist. 2022 Dec 15;15:7485-7494 [PMID: 36544993]
  14. Antimicrob Agents Chemother. 2002 Dec;46(12):3817-22 [PMID: 12435682]
  15. Sci Total Environ. 2019 Jul 1;672:618-624 [PMID: 30974353]
  16. Microbiol Spectr. 2022 Aug 31;10(4):e0201522 [PMID: 35950758]
  17. J Clin Microbiol. 2013 Jun;51(6):1762-8 [PMID: 23536409]
  18. J Glob Antimicrob Resist. 2019 Dec;19:284-293 [PMID: 31212107]
  19. BMC Microbiol. 2023 Feb 27;23(1):49 [PMID: 36850019]
  20. Antimicrob Resist Infect Control. 2018 Nov 19;7:137 [PMID: 30479750]
  21. EBioMedicine. 2017 May;19:98-106 [PMID: 28479289]
  22. Antimicrob Resist Infect Control. 2019 Jul 24;8:126 [PMID: 31367347]
  23. Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12868-12871 [PMID: 30559204]
  24. J Glob Antimicrob Resist. 2023 Sep;34:74-82 [PMID: 37394034]
  25. J Infect Dev Ctries. 2021 Jul 31;15(7):934-342 [PMID: 34343118]
  26. J Glob Antimicrob Resist. 2018 Dec;15:226-227 [PMID: 30339894]
  27. Infect Drug Resist. 2021 Apr 06;14:1325-1333 [PMID: 33854345]
  28. Infect Drug Resist. 2019 Mar 20;12:667-674 [PMID: 30936728]
  29. Microbiol Spectr. 2024 Feb 6;12(2):e0185523 [PMID: 38230935]
  30. Microbiol Spectr. 2023 Feb 21;:e0401022 [PMID: 36802220]
  31. J Antimicrob Chemother. 2016 Jun;71(6):1510-9 [PMID: 26945714]
  32. Biomed Res Int. 2014;2014:249856 [PMID: 24790993]
  33. FEMS Microbiol Rev. 2012 Mar;36(2):340-63 [PMID: 21707670]
  34. Lancet Infect Dis. 2016 Feb;16(2):161-8 [PMID: 26603172]
  35. Antimicrob Agents Chemother. 2018 Jan 25;62(2): [PMID: 29203488]
  36. Antimicrob Agents Chemother. 2013 Oct;57(10):5131-3 [PMID: 23836188]

MeSH Term

China
Humans
Tertiary Care Centers
Risk Factors
Anti-Bacterial Agents
Escherichia coli Infections
Male
Female
Microbial Sensitivity Tests
Middle Aged
Multilocus Sequence Typing
Escherichia coli
Adult
Carbapenems
Aged
beta-Lactamases
Bacterial Proteins
Carbapenem-Resistant Enterobacteriaceae
Plasmids
Young Adult
Child
Infant
Child, Preschool
Aged, 80 and over
Adolescent
Escherichia coli Proteins

Chemicals

Anti-Bacterial Agents
Carbapenems
beta-Lactamases
carbapenemase
Bacterial Proteins
Escherichia coli Proteins

Word Cloud

Created with Highcharts 10.0.0blaCRECisolatesfactorsstrainsidentifiedusedCP-CRECcoliChinatypeexpressionmcr-1RiskinfectionSTsfound0EscherichiamolecularcharacterizationriskFujiantotal48collectedclinicalresistancesequenceacrAacrBtolCConjugationassayscarryingproducingcarbapenemase75%21fiven = 1ST617non-CP-CREChighscoringsystemcarbapenemcausedpumpsBACKGROUND:seriouspublichealthconcernregardingemergencecarbapenem-resistantpurposestudyidentifyprovinceMETHODS:varioussamplesusingmatrix-assistedlaserdesorption/ionizationtime-of-flightmassspectrometryMALDI-TOF/MSSusceptibilityantibioticsdeterminedstandardbrothmicrodilutionmethodPolymerasechainreactionPCRscreencommondruggenesMultilocustypingMLSTRT-qPCRdetectgeneanalyzetransferabilityplasmidslogisticregressionanalysisRESULTS:8125%18no-CP-CRECbelongedunknownPerianalswabsmainsample25patientshematologicalmalignanciescontainn = 32n = 5amongoneisolateco-existenceTwobla-positivespecificallyco-haborconfirmed6822/32transferredEFour9deletionsompCompFproductionshowedAntibioticsusageantifungaltreatmentdetectionpathogenspriorrespiratorydiseaseindependentareareceiveroperatingcharacteristiccurve937Youden'sindexsensitivityspecificity9678maximal2pointsscoredCONCLUSIONS:primarilymultipletypeslossporinproteineffluxcoupledhighlydiversetermsSTfirstdescribestraineasy-to-usedevelopeddiagnoseinfectionsresistantrecoveredtertiaryhospital20212023NMDEffluxNo-CP-CRECfactormcr-1

Similar Articles

Cited By